TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31112476
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy followed by N-AVD
Study: 31113467
Drug: Serum Cyr61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Cyr61 concentration at baseline and 12 weeks after treatment in ACR responders
Study: 31113467
Drug: Serum Cyr61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Cyr61 concentration at baseline and 12 weeks after treatment in non-responders
Study: 31113837
Drug: Intravenous CPX-POM
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CPX-POM
Study: 31113837
Drug: Oral CPX-O
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CPX-O
Study: 31114268
Drug: Grazoprevir/elbasvir in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir/elbasvir in combination with peginterferon alfa plus ribavirin
Study: 31114846
Drug: Emactuzumab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab monotherapy
Study: 31114846
Drug: Emactuzumab in
Normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab in combination with paclitaxel (80 mg/m2 weekly)
Study: 31114846
Drug: Emactuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab (1000 mg every 2 weeks)
Study: 31114846
Drug: Emactuzumab (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab (monotherapy and combination)
Study: 31116389
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg per day
Study: 31116389
Drug: Real-time enoxaparin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time enoxaparin dose adjustment
Study: 31116405
Drug: Ovarian tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian tissue transplantation (OTT) after prior chemotherapy exposure
Study: 31116676
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (initiated in 675 patients, 97%); 600 (89%) treated with low-molecular-weight heparin
Study: 31118445
Drug: LDL-c <2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-c <2.6 mmol/L
Study: 31118571
Drug: 60-mg dexlansoprazole
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg dexlansoprazole
Study: 31118571
Drug: 40-mg esomeprazole
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg esomeprazole
Study: 31120195
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg coadministered with methadone
Study: 31120355
Drug: Palbociclib at
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib at 75 mg, 100 mg, or 125 mg on days 1-12 of each 21-day cycle plus intravenous bortezomib 1.0 mg/m²
Study: 31120585
Drug: Auto-titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-titration of EPAP during NIV
Study: 31121319
Drug: SRH (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRH (blood glucose≥11mmol/L in at least two samples during the first 3 days)
Study: 31122213
Drug: Circulating 25-hydroxyvitamin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating 25-hydroxyvitamin D levels above 50 nmol/L (sufficient)
Study: 31122213
Drug: Circulating 25-hydroxyvitamin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating 25-hydroxyvitamin D levels below 50 nmol/L (insufficient)
Study: 31122988
Drug: Assessment for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment for osteonecrosis using MRI scans of the lower limbs and physiotherapy assessment at various time points (within 4 weeks of diagnosis, end of delayed intensification, and 1, 2, and 3 years after the start of maintenance therapy)
Study: 31124321
Drug: Levetiracetam Monotherapy
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam Monotherapy
Study: 31124335
Drug: Osimertinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib treatment in T790M-positive tissue (n=45)
Study: 31124335
Drug: Osimertinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib treatment in T790M-positive plasma (n=54)
Study: 31124471
Drug: Game play
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Game play with treatment as usual
Study: 31124580
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg, carfilzomib 20/27 mg/m², dexamethasone (SKd)
Study: 31125423
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg with food
Study: 31125423
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg fasted
Study: 31126257
Drug: Controls (women
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls (women surgically intervened for breast augmentation or reduction)
Study: 31126287
Drug: Previous users
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous users of inhalation therapy
Study: 31126332
Drug: Nintedanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (200 mg/bid) plus letrozole (2.5 mg/day)
Study: 31126575
Drug: CAM treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM treatments (Acupuncture, Reflexology, Guided Imagery)
Study: 31127700
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and antiepileptics
Study: 31128146
Drug: Pencil beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pencil beam scanning proton beam radiation therapy (PBS-PT) with concurrent 5-fluorouracil (5-FU) and mitomycin C (MMC)
Study: 31128285
Drug: Cephalosporins (monotherapy)
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporins (monotherapy)
Study: 31128285
Drug: Tetracycline (monotherapy)
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline (monotherapy)
Study: 31128285
Drug: Macrolide (monotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide (monotherapy)
Study: 31128285
Drug: Cotrimoxazole (monotherapy)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (monotherapy)
Study: 31128285
Drug: Quinolones plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinolones plus carbapenems (combination therapy)
Study: 31128285
Drug: Quinolones (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinolones (sequential therapy)
Study: 31129440
Drug: New KoCARC
Approvals — FDA: no, EMA: no, PMDA: no
Description: New KoCARC TOR rules (combination of asystole and age > 60 years with current TOR rule)
Study: 31129514
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with bi- or quadrivalent HPV vaccine
Study: 31133863
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise regimen (resistance exercise + functional exercise)
Study: 31133899
Drug: Internet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based intervention for depression, details on dosage and duration not available
Study: 31136632
Drug: Anti-depressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-depressive therapy
Study: 31138229
Drug: PD-1 blockade
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 blockade (pembrolizumab) combined with radiation (3 × 8 Gy) and immune/environmental-targeting compounds (vitamin D, lansoprazole, aspirin, cyclophosphamide, curcumin)
Study: 31138588
Drug: Pyrotinib 160
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 160 mg, 240 mg, 320 mg, or 400 mg once daily plus capecitabine 1,000 mg/m²
Study: 31138588
Drug: Pyrotinib in
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib in combination with capecitabine
Study: 31139146
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment following POSEIDON criteria
Study: 31139431
Drug: VR-CBT intervention
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-CBT intervention (8 weekly group sessions)
Study: 31139441
Drug: No MAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: No MAM treatment
Study: 31139640
Drug: Fresh pomegranate
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh pomegranate juice (PJ) at 1.5 mL per kg body weight
Study: 31139766
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg folic acid/d (higher strength)
Study: 31139766
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg folic acid/d (standard of care)
Study: 31140667
Drug: Labels used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labels used to describe themselves and when speaking with others who use drugs, with family and with treatment providers
Study: 31142037
Drug: First-line triplet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line triplet or doublet chemotherapy combined with targeted therapy
Study: 31142450
Drug: Higher consumption
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher consumption of ultra-processed foods (>4 servings daily)
Study: 31142503
Drug: CIV rhIL15
Normalized name: succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIV rhIL15 at 2 μg/kg/day
Study: 31142503
Drug: CIV rhIL15
Normalized name: succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIV rhIL15 at various doses (0.125, 0.25, 0.5, 1, 2, or 4 μg/kg/day)
Study: 31143880
Drug: Trabectedin (T)
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin (T) at dose level 1 (1.5 mg/m2) in combination with radiation therapy (RT) (45 Gy in 25 fractions of 1.8 Gy each)
Study: 31145415
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of PF-06801591 at escalating doses (0.5, 1, 3, or 10 mg/kg) every 3 weeks
Study: 31145415
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of PF-06801591 at a single dose level of 300 mg every 4 weeks
Study: 31145415
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response rate for both intravenous and subcutaneous administration
Study: 31145415
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of PF-06801591
Study: 31145415
Drug: PD-1 receptor
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 receptor occupancy
Study: 31147146
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent cisplatin and radiation therapy (CRT)
Study: 31147302
Drug: GLPG1837 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1837 (three increasing dosages twice-daily for two 7-day and one 14-day period)
Study: 31148056
Drug: Conservative or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative or surgical treatment for LUTS/BPH
Study: 31148336
Drug: RIP3 promoter
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RIP3 promoter variant rs3212247 CC genotype
Study: 31151405
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 25M pCPC
Study: 31151405
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 50M pCPC
Study: 31151405
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of vehicle (Control)
Study: 31152555
Drug: Artemether-lumefantrine administered
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine administered twice daily for 3 days
Study: 31152705
Drug: REACH intervention
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACH intervention (combined outpatient and home PT with app and tablet)
Study: 31154457
Drug: Pembrolizumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, 200 mg, administered intravenously every 3 weeks for up to 35 doses.
Study: 31154919
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Study: 31154995
Drug: Counseling on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling on appropriate infant feeding and WASH practices for six months (monthly visits)
Study: 31155600
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (qHPV), administered in a three-vaccination regimen (Day 1, Months 2 and 6)
Study: 31156538
Drug: Parenteral Phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Phenobarbital
Study: 31156538
Drug: Parenteral Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral Phenytoin
Study: 31156861
Drug: Pharmacy care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy care intervention involving motivational interviews, delivered by community pharmacists face-to-face or by telephone, as part of the New Medicine Service or a Medication Usage Review, lasting 15-20 minutes.
Study: 31157039
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department
Study: 31157074
Drug: 90 mM trisodium
Normalized name: TRISODIUM DIPHOSPHATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mM trisodium citrate solution
Study: 31157074
Drug: 35 mM trisodium
Normalized name: TRISODIUM DIPHOSPHATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mM trisodium citrate solution
Study: 31157074
Drug: Both 35 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 35 mM and 90 mM trisodium citrate solutions
Study: 31157746
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.i.d. for 5 days
Study: 31157864
Drug: CEASE intervention
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEASE intervention with electronic tablet screener and motivational/educational videos; 2,764 smokers consented at visits.
Study: 31157864
Drug: CEASE intervention
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEASE intervention with electronic tablet screener; 2,764 smokers consented at visits.
Study: 31159817
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (157 patients)
Study: 31160383
Drug: TAK-228 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 (oral mTORC1/2 inhibitor) combined with TAK-117 (PI3Kα inhibitor)
Study: 31160383
Drug: TAK-228 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 (oral mTORC1/2 inhibitor) combined with paclitaxel (chemotherapy)
Study: 31161044
Drug: Sliding hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding hip screw (SHS) and vitamin D supplementation (4000 IU daily for 6 months)
Study: 31161044
Drug: Cancellous screws
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cancellous screws and vitamin D supplementation (4000 IU daily for 6 months)
Study: 31164456
Drug: GC1118 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 (5.0 mg/kg)
Study: 31164456
Drug: GC1118 (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 (4.0 mg/kg)
Study: 31164456
Drug: GC1118 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 in Cohort 1 (CRC without prior anti-EGFR treatment)
Study: 31164456
Drug: GC1118 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 in Cohort 2 (CRC with tumors resistant to anti-EGFR therapy)
Study: 31164926
Drug: Liraglutide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (titrated from 0.6 mg q.d. to 1.8 mg q.d. over 4 weeks)
Study: 31164926
Drug: Metformin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (titrated from 500 mg b.i.d to 1000 mg b.i.d. over 4 weeks)
Study: 31165541
Drug: Whole breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole breast once-weekly hypofractionated radiotherapy (wHF-RT) to a total dose of 30 Gy, in 5 fractions of 6 Gy
Study: 31166857
Drug: Bacterial fluorescence
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacterial fluorescence imaging in combination with clinical evaluation of signs and symptoms (CSS)
Study: 31167051
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (5.6 years of treatment)
Study: 31167060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no macrolide treatment)
Study: 31167654
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide (0.5 and 1.0 mg)
Study: 31167802
Drug: Oral idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral idasanutlin
Study: 31167965
Drug: COL7A1-modified autologous
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL7A1-modified autologous fibroblasts (3 intradermal injections of ~1 × 10^6 cells/cm2)
Study: 31168327
Drug: Adiponectin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin concentration increase of 1 µg/mL
Study: 31168494
Drug: Any other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other approved antiseizure drug (ASD)
Study: 31170515
Drug: Radical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical treatment options for higher risk prostate cancer
Study: 31170941
Drug: Healthy Primary
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Primary School of the Future (HPSF) initiative including daily free healthy lunches and structured physical activity sessions
Study: 31171638
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell transfusion dose density
Study: 31171735
Drug: Axitinib plus
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib plus Crizotinib (starting doses: axitinib 3 mg plus crizotinib 200 mg)
Study: 31172977
Drug: Dolutegravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir plus boosted-darunavir dual therapy
Study: 31174106
Drug: ICS/LABA/LAMA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA/LAMA therapy
Study: 31174106
Drug: Liquid oxygen
Normalized name: OXYGEN 99 L in 100 L RESPIRATORY (INHALATION) GAS [Liquid Oxygen]
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid oxygen therapy
Study: 31174106
Drug: ICS/LABA or
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA or ICS/LABA/LAMA associated therapy
Study: 31175167
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for 3 weeks per 4-week cycle
Study: 31177537
Drug: Vorinostat (SAHA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (SAHA), cladribine 5 mg/m², and rituximab (SCR)
Study: 31177991
Drug: Intratumoral injections
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injections of LTX-315 (oncolytic peptide)
Study: 31178096
Drug: L-DOPA Monotherapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA Monotherapy
Study: 31178096
Drug: Ineffective antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineffective antidepressant medication taper
Study: 31179103
Drug: β-blockers (metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (metoprolol tartrate/metoprolol succinate/Bisoprolol Fumarate) within 24 hours of perioperative period
Study: 31179103
Drug: Non-β-blockers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-β-blockers
Study: 31179386
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) with loading dose
Study: 31180977
Drug: Opioid dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid dosage
Study: 31180977
Drug: Opioid use/dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid use/dosage
Study: 31183469
Drug: Drug choices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug choices for sedation; midazolam was the most preferred agent (90.0%).
Study: 31183813
Drug: Eltrombopag (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (25, 50, 75, or 100 mg once daily)
Study: 31183813
Drug: Eltrombopag (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (continued treatment)
Study: 31183813
Drug: Eltrombopag (discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (discontinued treatment)